Cognitive Decline Slowed With Cognitive Remediation in At-Risk Adults
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, Nov. 1, 2024 -- For older adults at risk for cognitive decline, especially those with remitted major depressive disorder (rMDD), with or without mild cognitive impairment (MCI), cognitive remediation (CR) plus transcranial direct current stimulation (tDCS) is effective for slowing cognitive decline, according to a study published online Oct. 30 in JAMA Psychiatry.
Tarek K. Rajji, M.D., from the Campbell Family Mental Health Research Institute in Toronto, and colleagues examined the efficacy of CR plus tDCS targeting the prefrontal cortex in older adults with rMDD, MCI, or both. A total of 486 older adults provided consent; 375 received at least one intervention session.
The researchers found that CR and tDCS slowed cognitive decline in older adults with rMDD or MCI during a median follow-up of 48.3 months (adjusted z score difference at month 60, 0.21; 95 percent confidence interval, 0.07 to 0.35). CR and tDCS did not improve cognition acutely in the preplanned primary analysis (adjusted z score difference at month 2, 0.06; 95 percent confidence interval, −0.006 to 0.12). There was a weak and not significant effect seen for CR and tDCS on delaying progression from normal cognition to MCI or from MCI to dementia (hazard ratio, 0.66; 95 percent confidence interval, 0.40 to 1.08). Treatment effects were seen for executive function and verbal memory in preplanned analyses; interactions were seen with diagnosis and APOE ε4, indicating a larger effect for those with rMMD and for APOE ε4 noncarriers.
"Our trial demonstrated the efficacy of a combined therapy of CR and tDCS in slowing cognitive decline in a high-risk sample," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-02 12:00
Read more
- Data presented from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis
- UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
- Cancer Incidence Increased for People With Multiple Sclerosis
- 2008 to 2022 Saw Rise in Industry-Sponsored Adult Cancer Clinical Trials
- Were FDA's 'Black Box' Warnings on Antidepressants a Mistake? Youth Suicides Rose Afterwards
- Love Bread & Pasta? Humans' Hunger for Carbs Has Ancient Roots
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions